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ABSTRACT 
 
Objective: To evaluate if serum levels of candidate ovarian cancer biomarkers vary with 
individual characteristics of healthy women who are likely candidates for an ovarian 
cancer screening program.  Methods: We analyzed serum CA125, mesothelin and HE4 
levels in a sample of 155 healthy post-menopausal women at increased risk for 
developing ovarian cancer based on personal and family cancer history.  Information on 
reproductive, family and medical histories, lifestyle factors and anthropometry was 
collected by self-report.  Twenty-two factors were examined using univariate and 
multiple linear regression models for the three biomarker levels.  Results:  In the 
multivariate models, CA125 levels were significantly higher in women who had used 
talcum powder (P=0.02) and were lower in women who were parous (P=0.05).  
Mesothelin levels were significantly higher in older women (P=0.01) and lower in 
heavier women (P=0.03). HE4 levels were higher in older women (P=0.001) and in 
women who began menstruating at an older age (P=0.03).   Conclusions:  CA125, 
mesothelin and HE4 levels in healthy, post-menopausal women at increased risk for 
ovarian cancer are significantly associated with a few ovarian cancer risk factors.  Since 
the effects of these personal characteristics on these serum markers are not large, their 
incorporation in screening algorithms may be unnecessary. This is true especially if a 
longitudinal algorithm is used because the marker level at the previous screen reflects 
personal characteristics such as age, BMI, and age of menarche.  Understanding the 
influence of personal factors on levels of novel early detection markers in healthy, 
unaffected women may have clinical utility in interpreting biomarker levels.  
 
   2
INTRODUCTION 
Considerable effort is underway to identify screening strategies that accurately 
diagnose ovarian cancer in its early stages when it is most treatable (1).  Biomarkers that 
can be measured in blood products are of particular interest for their potential to provide 
a low-cost, noninvasive screening modality suitable for application to large populations. 
CA125 is the most commonly used currently available ovarian cancer biomarker (1, 2).  
It is a high-molecular weight glycoprotein that is elevated in the serum of 75% to 90% of 
patients with epithelial ovarian tumors (3). It is employed as a diagnostic tool for ovarian 
cancer (4), to assess response to ovarian cancer treatment (5) and to monitor for 
recurrence (6).  As a diagnostic marker CA125 is associated with a high false-positive 
rate among women with benign gynecologic conditions (7) and its sensitivity in early 
stage disease is inadequate (1). When used to screen asymptomatic postmenopausal 
participants in the Prostate, Lung, Colorectal and Ovarian Cancer Screening trial, 
abnormal CA 125 levels were found in 1.4% of the women and the positive predictive 
value for CA125 was only 3.7% (after excluding tumors of low malignant potential) (8).  
  The identification of new cancer biomarkers to replace or complement CA125 is 
urgently needed and currently underway (6).  Mesothelin (1, 9-11) and HE4 (12, 13) are 
two of the most promising novel ovarian cancer biomarkers and are of particular interest 
as candidate early detection markers. Their diagnostic performance has been well-studied 
and they are recognized for their ability to complement CA125.  Briefly, mesothelin is an 
epithelial biomarker that predicts ovarian cancer with sensitivity levels of 38% and 27% 
at 95% and 98% specificity, respectively (14).  The AUC for cases versus controls is 
>0.70 (14). In addition, mesothelin has been shown to improve the diagnostic 
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performance of CA125.  Results from McIntosh et al. (15) demonstrate that sensitivity at 
98% specificity increases from 79% for CA125 alone to 87% when CA125 is used in a 
composite marker with mesothelin.  HE4 is commonly overexpressed in ovarian cancer 
tissue and elevated in the serum of patients with ovarian cancer (13, 16). The sensitivity 
of HE4 is 62% at 95% specificity and 55% at 98% specificity, and the AUC value for 
cases versus controls is >0.84 (14). These levels of sensitivity and specificity rival those 
of CA125, particularly in distinguishing patients with ovarian cancer from those with 
nonmalignant gynecologic conditions (12). Immunohistochemical analysis of HE4 has 
been reported to complement CA125, identifying 32% of cancers that do not express 
CA125 (10). 
The application of biomarkers to ovarian cancer early detection, including their 
validation in serial preclinical samples such as those from the Prostate, Lung, Colorectal 
and Ovarian Cancer Screening trial or the Women’s Health Initiative, requires the 
development of algorithms or decision rules that select women for additional testing 
and/or diagnostic surgery.  Since the prevalence of ovarian cancer is low and definitive 
diagnosis requires expensive and potentially morbidity-causing surgery, high specificity 
for a screening program is required. Recent research has focused on evaluating change 
over time in marker levels and strategies for combining markers into panels (17-19).  
These approaches generally aim to improve lead-time and sensitivity while maintaining 
specificity. Importantly both screening thresholds and specificity depend largely on the 
behavior of biomarkers in healthy, unaffected women. Therefore it is plausible that 
overall screening performance can be improved by accounting for factors influencing the 
level of markers in healthy, unaffected women.  
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Furthermore, before clinical utility of the markers for early detection can be 
established through a prospective randomized controlled trial, they must be validated in 
preclinical samples obtained prior to diagnosis. Such samples were collected in the 
Prostate, Lung, Colorectal and Ovarian Cancer Screening trial and in the Women’s 
Health Initiative, and are becoming available for validation purposes.  If patient 
characteristics other than presence or absence of disease have a noteworthy influence on 
marker levels and these effects are not accounted for in selecting thresholds for positivity, 
the performance of the markers for disease classification may be impaired.  The objective 
of this study was to identify and quantify the effects of personal characteristics, including 
lifestyle factors, on the levels of three promising candidate ovarian cancer early detection 
markers: CA125, mesothelin and HE4. We focused our research on postmenopausal 
women at increased ovarian cancer risk since these women are ideal candidates for 
testing novel ovarian cancer screening strategies.   
 
MATERIALS AND METHODS  
Study Population  
The women included in this report are participants in the Seattle-based Ovarian 
Cancer Early Detection Study (OCEDS).  This was an Institutional Review Board-
approved study initiated in 2003 to evaluate screening using longitudinal CA125 levels 
and transvaginal sonography for the early detection of ovarian cancer in women at 
increased risk for the disease based on personal or family history of breast cancer, family 
history of ovarian cancer, or the presence of a BRCA 1 or 2 mutation among first or 
second degree relatives.  Specific OCEDS eligibility criteria are outlined in Table 1.  All 
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participants provided informed consent prior to enrollment. The screening protocol 
involved CA125 measurements at baseline and quarterly thereafter.  Longitudinal CA125 
values were interpreted using the parametric empirical Bayes method (17, 18), which 
evaluates within women changes over time in CA125 levels.  Screening using 
transvaginal sonography was conducted at baseline and annually thereafter. Additional 
transvaginal sonography examinations were conducted at follow-up for women with 
elevated CA125 results.   
OCEDS participants were considered eligible for this study if they did not report 
bilateral oophorectomy and if they were 50+ years of age or post-menopausal at the time 
of a blood collection for which serum biomarker levels were available.  For women <50 
years of age, menopausal status was defined by self-reported natural menopause, use of 
hormone replacement therapy (HRT), or reported hysterectomy.  Of the 285 women 
enrolled in OCEDS at the time of this report, 155 were eligible for this study (Figure 1).  
All women in the defined study population were followed for ovarian cancer 
incidence through data linkage to the Puget Sound Surveillance Epidemiology and End 
Results cancer registry for 2 years from the date of the blood sample that was used in our 
analyses. 
 
Defining the Personal Characteristics  
Data related to reproductive history, personal or family diagnoses of cancer, 
overall health issues (such as hospitalization or surgery), medical information directly 
related to ovarian and breast health, use of medications, and personal habits including 
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smoking and caffeine use were obtained from self-administered OCEDS questionnaires 
and were measured by self-report.  The personal characteristics previously studied by 
Pauler et al. (20) for influencing CA125 levels in healthy, postmenopausal average risk 
women were examined, including age, personal history of breast cancer, age at menarche, 
race, parity, hysterectomy, and use of oral contraceptives, HRT, talcum powder, tobacco, 
and caffeine.  We also evaluated self-reported height, weight, fertility drug use, pain 
medication use, and tubal ligation.  Since the focus of this research is on high-risk 
women, we also evaluated the influence of having a BRCA1/BRCA2 mutation, a first-
degree relative with ovarian cancer, a second-degree relative with ovarian cancer, a first-
degree relative with breast cancer, or a second-degree relative with breast cancer.  
Data on current age was calculated based on the date of the blood draw and the 
self-reported birth date.  Body mass index (BMI; in kg/m2) was calculated for subjects 
who provided data for both height and weight. Race was defined as white or non-white 
based on self-report of any race other than white or Caucasian. Being parous was defined 
as reporting having had at least one pregnancy that lasted beyond 6 months (all 
deliveries, both term and preterm). A caffeine user includes individuals reporting current 
consumption of one or more cups of coffee per day.  Smokers include participants 
reporting current or previous smoking.  In addition, the number of self-reported cigarettes 
smoked per day was assessed.  A talcum powder user is defined as an individual 
reporting current or past application of talcum powder to the genital area one or more 
times per month. Individuals who report genetic testing that demonstrates BRCA1 or 
BRCA2 mutations are defined as mutation carriers or carriers of variants with 
undetermined significance. HRT use was defined as ever taking pills that contained 
   7
female hormones, such as estrogen or estrogen plus progesterone (other than birth control 
pills).  Hormonal contraceptive use was defined as reporting ever having used birth 
control pills, patches, or implants. Fertility drug use was defined as reporting ever having 
ever taken drugs to stimulate ovulation. Pain medication use was defined as reporting 
ever having used aspirin, Tylenol, nonsteriodal anti-inflammatory drugs, or similar drugs. 
For family history of ovarian or breast cancer, a first-degree relative was defined as a 
parent, sibling, or child.  Second-degree relatives include grandmothers, aunts, and 
nieces. Personal history of breast cancer was defined as having breast cancer prior to 
enrollment in OCEDS.  
 
 
Measurement of CA125, HE4 and Mesothelin  
 
All biomarkers were measured in serum by sandwich ELISA on a Luminex 
platform without multiplexing.  Monoclonal antibodies (mAb) were used in the assays for 
CA125 and HE4 (21); a commercially available polyclonal antibody and a novel biobody 
(22) were used in the mesothelin assay (14). 
CA125 and HE4 serum levels were assessed using bead based immunoassays 
performed as described by Scholler et al. (21). Briefly, complementary anti-CA125 mAbs 
X306 and X52 were purchased from Research Diagnostics, Inc (RDI). Complementary 
anti-HE4 mAbs 3D8 and 2H5 were kind gifts from Dr. Ingegerd Hellstrom (12).  Anti-
CA125 X52 mAb and anti-HE4 3D8 mAb were biotinylated using the EZ-Link sulfo-
NHS-biotinylation kit (Pierce) according to the manufacturer’s instructions and dialyzed 
against PBS (Fisher BioReagents) using a dialysis slide (Slide-a-Lyzer 7kDa molecular 
weight cutoff; Pierce). Biotinylated detection antibodies were incubated with 
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phycoerythrin-conjugated streptavidin (Bio-Rad Laboratories Inc., or Becton Dickinson 
Pharmingen). Bead-based assays were carried out in 96-well MultiScreen GV filter plates 
(Millipore Corporation) using a vacuum manifold (Millipore) to drain assay reagents. For 
conjugating anti-HE4 2H5 to beads, bead activation buffer was made with 0.1 mol/L 
sodium phosphate (NaH2PO4; pH 6.2; Sigma-Aldrich). 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (Pierce) and N-
hydroxysulfosuccinimide (Pierce) were diluted to 38 mg/mL and to 109 mg/mL, 
respectively in activation buffer. The coupling buffer was made with 0.05 mol/L of 2-(N-
Morpholino) ethanesulfonic acid (pH 5.0; Sigma-Aldrich). PBS supplemented with 1% 
bovine serum albumin was used for bead blocking and storage buffers. Anti-CA125 
X306 was conjugated to beads using a Bio-Plex amine coupling kit (Bio-Rad). All 
incubations were carried out for 30 minutes (unless otherwise specified) in PBS 
supplemented with 1% bovine serum albumin (Sigma-Aldrich) for HE4 and mesothelin 
assays, and assay buffer (Bio-Rad) for CA125 assays. Washes were performed with PBS 
supplemented with 0.05% Tween 20 (Sigma-Aldrich) for HE4 and mesothelin assays and 
wash buffer (Bio-Rad) for CA125 assays. Plates were analyzed with the Bio-Plex Array 
reader (Bio-Rad). 
For the CA125 assay, 5 μg/mL of anti-CA125 mAb X306 was coupled to 
carboxy-coated beads. Antibody-coated beads were incubated with 4-fold diluted patient 
sera and captured antigen was detected with 2 μg/mL of biotinylated anti-CA125 mAb 
X52 followed by SA-PE. This procedure has been found to yield values that are strongly 
correlated (r >0.90) with the research standard CA125II RIA from Fujirebio Diagnostics, 
Inc. (FDI) (21).  For the HE4 assay, anti-HE4 2H5 was coupled to beads at a 
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concentration of 10 μg/mL.  Antibody-coated beads were incubated with 10-fold diluted 
sera. Captured antigens were detected with 2 μg/mL of biotinylated 3D8 followed by a 10 
minute incubation with 1000-fold diluted phycoerythrin-conjugated streptavidin.  The 
bead-based HE4 assay yields values that are strongly correlated (r =0.95) with a plate-
based assay using the same mAbs (21).  
 The mesothelin bead-based assay employed a polyclonal antibody and a novel 
biobody and was conducted as previously described (14).  The anti-mesothelin polyclonal 
antibody (pAb) was purchased from R&D Systems. The complementary anti-mesothelin 
antibody was an in vivo biotinylated single-chain Fragment variable secreted by yeast 
(biobody no. 7) (23). Biobodies were preincubated with PJ31S PhycoLink Streptavidin-
R-Phycoerythrin (Prozyme).  For the bead-based assays, carboxy-coated beads were 
conjugated to anti-mesothelin polyclonal antibody at a concentration of 50 μg/mL.  To 
capture antigen, antibody-coated beads were incubated with 5-fold diluted sera. Biobody 
no. 7 at a concentration of 1 ug/mL was preincubated with 2,000-fold diluted PJ31S on 
ice and in the dark. Bead-captured antigens were detected with biobodies preincubated 
with PJ31S.  This novel assay correlates well with a bead-based assay using anti-
mesothelin mAbs (14).   
 
Statistical Methods 
 Serum levels of CA125, mesothelin and HE4 were log-transformed and 
standardized to have mean 0 and SD 1. This transformation induces the same 
measurement scale for all three markers, allowing them to be easily compared to one 
another (24). 
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Univariate linear regression methods (25) were used to evaluate the association of 
each personal characteristic with CA125, HE4 and mesothelin levels. For analysis 
purposes, women who did not report a condition or use of a medication were assumed not 
to have the condition or use the medication. Factors that yielded a P ≤ 0.20 in the 
univariate models were included in a multivariate linear regression model (25) for each 
marker and backwards elimination methods (26) were applied to yield the model 
reported.  In this approach, all of the selected factors are included in the initial model and 
then the variable with the highest P value is eliminated from the model in a stepwise 
fashion until all of the remaining variables are statistically significant. The overall 
predictiveness of the model is summarized by an R2 statistic, which can be interpreted as 
the fraction of variation in biomarker levels that is “explained” by the variables included 
in the model.  
STATA statistical software package (version 9.0, Stata Corporation) was used for 
these analyses. All statistical tests were two-sided and considered to be statistically 
significant at P < 0.05.   
 
RESULTS 
 Data for the personal characteristics and lifestyle factors included in our analyses 
were obtained from self-report.  The following characteristics had 100% response rate: 
age at blood draw, age at menarche, hormone contraceptive use, family history of breast 
cancer, and family history of ovarian cancer.  A <5% nonresponse rate was obtained for 
the following characteristics: height, weight, BMI, race, parity, talcum powder use, HRT 
use, fertility drug use, hysterectomy, tubal ligation, and personal history of breast cancer.  
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Report of caffeine consumption, smoking, use of pain mediation, and BRCA1/BRCA2 
mutation was missing for 18%, 59%, 22%, and 83% of the women, respectively. All of 
the women who self-reported smoking included the total number of cigarettes smoked 
every day.  
Table 2 summarizes the personal characteristics and lifestyle factors in this study 
population. Median age of the women was 55 years. In this high-risk population, 49.0% 
reported a personal history of breast cancer, 63.2% reported one or more first-degree 
relatives with breast cancer, 34.8% reported one or more first-degree relatives with 
ovarian cancer, and 5.2% reported having a BRCA1/BRCA2 mutation. 
The univariate linear regression results for CA125, mesothelin and HE4 are 
reported in Table 3. Since the marker values were log-transformed and standardized, each 
factor’s coefficient can be interpreted as the deviation from zero for a one unit change in 
the corresponding factor. For example, talcum powder use was associated with a 0.32 SD 
increase in the log-transformed CA125 levels (P=0.04).  The log-transformed mesothelin 
levels increased 0.02 SD for every 1 year increase in age (P=0.05) and 0.04 SD for each 
additional cigarette smoked per day (P=0.03).  Similarly, the log-transformed HE4 levels 
increased 0.06 SD for every 2 year increase in age (P<0.001), 0.14 SD for every year 
increase in age at menarche (P= 0.03), 0.40 SD among parous women (P=0.03), and 0.37 
SD among women who consumed at least one cup of coffee per day (P=0.04); HE4 levels 
decreased 0.35 SD among women who reported one or more second-degree relatives with 
breast cancer (P=0.05).  
Using these univariate analyses to guide variable selection for the multivariate 
modeling, the initial multivariate model for CA125 included parity, number of cigarettes 
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smoked per day, talcum powder use, HRT, use of pain medications, and reported first-
degree relative(s) with ovarian cancer.  The initial multivariate model for mesothelin 
included age at the time of blood draw, weight, body mass index, number of cigarettes 
smoked per day, known BRCA1/BRCA2 mutation, and first-degree relative(s) with 
breast cancer. For HE4 the model began with age at the time of blood draw, age at 
menarche, parity, coffee use, number of cigarettes smoked per day, talcum powder use, 
known BRCA1/BRCA2 mutation, HRT, hormonal contraception use,  first-degree 
relative(s) with breast cancer, and second-degree relative(s) with breast cancer.  
After backwards elimination of nonsignificant predictors, the final multivariate 
models suggest that these personal characteristics explain a fraction of biomarker 
variability (4% for CA125, 6% for mesothelin, and 22% for HE4) (Table 4). Talcum 
powder use was associated with a 0.39 SD increase (P=0.02) and parity was associated 
with a 0.28 SD decrease (P=0.05) in CA125 levels.  Mesothelin levels increased 0.02 SD 
for every year increase in age at the time of blood draw (P=0.01) and decreased 0.04 SD 
for every unit change in BMI (kg/m2; P=0.03).  HE4 levels increased 0.06 SD for every 
year increase in age at the time of blood draw (P=0.001) and 0.13 SD for every year 
increase in menarche (P=0.03).   
 
DISCUSSION  
Early detection is a critical focus of ovarian cancer research because of its 
potential to reduce suffering and morbidity.  One promising screening strategy involves 
using change over time in a panel of serum markers that includes CA125 to select women 
for additional testing with imaging.  The application of biomarkers and biomarker panels 
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to ovarian cancer early detection requires the development of algorithms or decision rules 
that improve sensitivity and maintain high specificity.  Since the behavior of markers in 
healthy, unaffected women largely defines screening thresholds and hence specificity, we 
undertook this study to evaluate personal factors that influence the levels of CA125, 
mesothelin and HE4 in healthy, high-risk postmenopausal women.  
Our analysis demonstrates that serum levels of all three candidate ovarian cancer 
early detection markers are significantly associated with a few personal characteristics of 
women.  In the final multivariate models, CA125 levels appear to track with some 
documented ovarian cancer risk factors: CA125 is higher in talcum powder users and is 
lower in parous women. Similarly, age was a significant predictor of higher mesothelin 
and HE4 levels.  We also observed an inverse correlation between mesothelin and BMI.  
While statistically significant, the impact of these factors on marker levels is not large, 
suggesting that rarely will these variables need to be accounted for in decision rules that 
include these specific markers.  The largest effects were noted for CA125 where talcum 
powder use was associated with a 0.39 SD increase (P = 0.02) and being parous was 
associated with a 0.28 SD decrease (P = 0.05).  These factors explained only 4% of the 
variability in CA125 levels, suggesting there is limited value in adjusting screening 
thresholds for these factors. However, age at the time of the blood-draw and age at 
menarche explained 22% of the variability in HE4 levels.  Although these factors are 
statistically significant, their relevance to screening algorithms and the decision for 
whether these covariates need to be adjusted for screening algorithms, may depend on the 
intended screening algorithm. Although cross-sectional rules might need to account for 
some of these effects, longitudinal algorithms, which are adjusted based on previous 
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marker values, do not, as long as the covariates are not time-varying. Variables that do 
not vary by time, or that vary according to predicable trends (such as age), will be 
adjusted for automatically and efficiently by the previous screening history measurement 
(17). The most comprehensive study of the influence of personal characteristics on 
CA125 levels among healthy women was provided by Pauler et al. (20).  In a sample of 
18,748 ovarian cancer-free postmenopausal women, the personal factors that significantly 
lowered CA125 levels included hysterectomy, smoking, and caffeine consumption. 
Conversely, CA125 levels significantly increased with age of menarche, age of 
menopause, and among women with a prior non-ovarian cancer diagnosis or a history of 
ovarian cysts. Race also significantly influenced CA125 levels in this population, with 
Caucasian women having the highest levels of CA125, followed by Asian women and 
then African women. In the current study of high-risk women, associations in the same 
direction were found but they were not statistically significant, perhaps because of the 
much smaller sample size (although important differences in study populations cannot be 
ruled out).  We found talcum powder use and parity to be significant predictors of CA125 
levels, neither of which were identified by Pauler et al.  These results could reflect the 
high risk women in the current study or they could represent a chance finding.  
Confirmation in other studies would help to clarify the importance of these effects.  
We believe this is the first report to describe factors that influence levels of the 
novel markers HE4 and mesothelin in healthy women.  We found that age was a 
significant predictor of both HE4 and mesothelin levels.  The results of our analysis also 
revealed a significant negative trend between BMI and mesothelin levels. Interestingly, a 
negative correlation between BMI and prostate-specific antigen has been reported in men 
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40 to 59 years of age (27).  Given the minimal effort required to collect age information 
and calculate BMI, these personal attributes could easily be adjusted for when evaluating 
cancer biomarker levels.   
Our sample size limits our ability to detect associations of less than a third of a 
standard deviation between the lifestyle factors and the biomarker levels. Additional 
limitations include imprecise information on menopausal status and reliance on self-
reported information particularly for variables with high social desirability attributes 
(e.g., weight, BMI, smoking). Of the personal attributes we found to be significant 
predictors of the biomarker levels, BMI is most likely to have high misclassification 
rates. In fact, it has been shown that study participants will often overestimate their height 
and underestimate their weight (27), both of which could introduce bias. We are unable to 
separate the effects of estrogen from progestin on biomarker levels.  The frequency of 
minority women, documented mutation carriers and fertility drug use was too low to 
provide reliable estimates of their effects.   
Since we did not adjust for multiple comparisons, some of our findings are likely 
to be false positives.  The Bonferroni method of adjustment (in which alpha is divided by 
the total number of comparisons) substantially limits the likelihood of a type I error, but 
may be too conservative in this setting since we evaluated the influence of 22 factors on 
three biomarkers (i.e.: resulting in a total of 66 comparisons).  In this scenario, we would 
expect approximately three of our statistically significant results to be obtained by chance 
alone.  However, despite this fact, our results suggest that some personal characteristics 
may influence the levels of the biomarkers.  These factors may be appropriately 
accounted for by using longitudinal screening algorithms for ovarian cancer screening. 
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This analysis examined a high-risk postmenopausal population. Our objective was 
to determine whether individual characteristics influence levels of ovarian cancer 
biomarkers in women who are most likely to participate in an ovarian cancer screening 
program. We excluded 35 women who reported bilateral oophorectomy since women 
without ovaries are unlikely to participate in this type of cancer screening program. In a 
sensitivity analyses, we repeated these analyses including these women.  The results did 
not change for CA125 or mesothelin. When women with bilateral oophorectomy were 
included in the analysis of HE4, age at menarche was no longer statistically significant.  
 The primary objective of this study was to evaluate the influence of personal 
characteristics, including lifestyle factors on levels of promising ovarian cancer early 
detection markers in a population of ostensibly healthy high-risk postmenopausal women 
likely to participate in a screening program. We identified a few personal factors that are 
significantly associated with levels of CA125, HE4 or mesothelin, but statistical 
significance does not imply clinical relevance or discriminatory power (28). Our findings 
provide important reassurance that screening algorithms based on these three markers 
need not include complicated adjustments for these variables, especially if a longitudinal 
algorithm such as the parametric empirical Bayes method (17) is employed because it 
inherently accounts for personal characteristics that may change systematically over time 
(such as age) as well as those that differentiate among women. Larger studies evaluating 
the influence of personal factors on the levels of novel early detection markers in healthy 
individuals will be needed as retrospective and prospective validation studies go forward. 
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Figure 1.  Eligibility schema of the decision rule used to define menopause status and 
derive the defined study population.  
 
 
 
 
 
 
 
Defined Study 
Population 
(n=155) 
Included in the analysis for the 
following reasons (n = 35): 
 
 - Reported natural menopause (n= 32) 
 - Reported periods are continuing due 
to  HRT (n=3) 
Excluded from the analysis for the 
following reasons (n = 95): 
 
- Still reporting menses 
- Reported hysterectomy (n= 3) 
 
Table 1. OCEDS inclusion and exclusion criterion.  
Inclusion Criteria 
1. Women must meet one of the following criteria to be considered high-risk for ovarian cancer: 
 The family contains at least two ovarian or breast cancers among the subject or first and 
second degree relatives of the subject.  This condition is satisfied by multiple primary cancers 
in the same person.  Where breast cancer is required to meet this criterion, at least one breast 
cancer must be pre-menopausal (age at diagnosis less than 50 years if age at menopause is 
unknown). 
 The subject is of Ashkenazi Jewish ethnicity with one first degree or two second degree 
relatives with breast cancer, or the subject is of Ashkenazi ancestry and has had breast cancer 
herself. Where breast cancer is required to meet this criterion, at least one breast cancer must 
be pre-menopausal (age at diagnosis less than 50 years if age at menopause is unknown).. 
 The subject has tested positive for a BRCA I/II mutation  
 The subject has a first or second degree relative with a BRCA I/II mutation. 
 
Exclusion Criteria  
The subject is, has, or has had one of the following criteria: 
1. Ovarian cancer or peritoneal carcinomatosis. 
2. A first or second degree relative with a BRCA I/II mutation and she had tested negative for the same 
mutation herself. 
3. Has no ovaries and has not tested positive for a BRCA I/II mutation. 
4. Less than 30 years of age. 
5. Currently pregnant or anticipating pregnancy during the study. 
6. Participating in other ovarian cancer early detection trials. 
7. Psychiatric or psychological or other conditions which prevent a fully informed consent. 
8. Currently untreated malignancy (other than non-melanoma skin cancer). 
9. Currently receiving adjuvant chemotherapy or radiation therapy for cancer (excluding tamoxifen).  
Patients who are being treated for local disease may enroll 3 months after completion of the last 
treatment (excluding tamoxifen). 
10. Treatment (excluding tamoxifen) for prior metastatic malignancy within the past five years. 
11. Intraperitoneal surgery within the last 3 months (laparoscopy or laparotomy). 
12. A history of any medical conditions that would place the subject at risk as a result of the blood 
donation.  Such conditions include but are not limited to: hemophilia or other bleeding disorders, 
chronic infectious disease, emphysema or serious anemia.  
 
 
 
 Table 2.  Distribution of the personal characteristics among the study population.  
 
Lifestyle Factors*  
Study Population  
(n=155) 
Personal Characteristics  
Age at blood draw -years, median (range) 55 (32-83) 
Age at menarche - years, median (range) 12 (9-17) 
Height - inches, median (range)± 65 (55-72) 
Weight - lbs, median (range) П 149 (105 – 282) 
BMI - kg/m2, median (range) δ 24.8 (17.4 – 43.9) 
Race - non-white, n (%) 3 (1.9) 
Parous - at least one birth, n (%) 102 (65.8) 
Caffeine - currently consume one or more cups of coffee per day, n (%) 69 (44.5) 
Smoker – current for former, n (%) 29 (18.7) 
    Number of cigarettes smoked per day, median (range) 10 (1 – 20) 
Talcum powder - ever used one or more times per month, n (%) 39 (25.2) 
BRCA1/BRCA2 Mutation Carrier, n (%) 8 (5.2) 
Medication Use  
HRT - (estrogen, progesterone, or both), n (%) 60 (38.7) 
Hormonal Contraceptives - ever use oral birth control, patches, implants, n (%) 121 (78.1) 
Fertility Drugs - ever use, n (%) 12 (7.7) 
Pain Medication - ever use Aspirin, Tylenol, Ibuprofen, etc., n (%) 114 (73.5) 
Gynecologic Surgery  
Hysterectomy, n (%) 16 (10.3) 
Tubal ligation, n (%) 34 (21.9) 
Cancer History  
Personal history of breast cancer, n (%) 76 (49.0) 
One or more 1° relatives with breast cancer, n (%) 98 (63.2) 
One or more 2 ° relatives with breast cancer, n (%) 100 (64.5) 
One or more 1° relatives with ovarian cancer, n (%) 54 (34.8) 
One or more 2° relatives with ovarian cancer, n (%) 42 (27.1) 
* Data on the lifestyle factors were obtained from self-report.  
± Data for height is missing for 2 subjects.  
П Data for weight is missing for 3 subjects. 
δ BMI was calculated from self-reported height and weight. The results exclude 4 subjects with missing BMI data.  
 
 
 Table 3.  Univariate linear regression results for the association between each personal characteristic and CA125, mesothelin, and HE4. 
CA125 Mesothelin HE4  
 
Covariates coefficient
* p-value coefficient* p-value coefficient* p-value 
Personal Characteristics       
Age at blood draw – years -0.003 0.75 0.02 0.05 0.06 <0.001 
Age at menarche – years 0.01 0.80 0.07 0.26 0.14 0.03 
Height at baseline – inches -0.003 0.90 -0.01 0.63 -0.02 0.57 
Weight at baseline – lbs -0.004 0.87 -0.004 0.10 -0.001 0.79 
Body Mass Index - kg/m2 -0.001 0.95 -0.03 0.08 -0.003 0.87 
Race - non-white  -0.49 0.33 -0.22 0.73 -0.35 0.58 
Parous - at least one birth  -0.20 0.18 0.07 0.70 0.40 0.03 
Coffee drinker - currently consume >1 cups of coffee per day  -0.08 0.56 0.103 0.55 0.37 0.04 
Number of cigarettes smoked per day -0.03 0.09 0.04 0.03 0.03 0.10 
Talc – ever used one or more times per month  0.32 0.04 0.19 0.55 0.37 0.06 
BRCA1/BRCA2 Mutation Carrier -0.15 0.64 -0.67 0.08 -0.74 0.06 
Medication Use       
HRT - (estrogen, progesterone, or both) 0.23 0.11 0.16 0.37 0.30 0.10 
Hormonal Contraceptives - ever use birth control, patches, implants 0.06 0.71 0.06 0.76 -0.32 0.13 
Fertility Drugs - ever use -0.31 0.40 0.40 0.36 -0.32 0.48 
Pain Medication - ever use Aspirin, Tylenol, Ibuprofen, etc. 0.29 0.07 0.21 0.27 -0.03 0.88 
Gynecologic Surgery       
Hysterectomy 0.02 0.94 0.26 0.35 -0.18 0.53 
Tubal Ligation 0.20 0.23 0.08 0.70 0.17 0.41 
Cancer History       
Personal history of breast cancer -0.13 0.35 0.13 0.43 -0.08 0.64 
One or more 1° relatives with breast cancer -0.12 0.42 0.27 0.13 -0.33 0.07 
One or more 2 ° relatives with breast cancer 0.14 0.35 -0.05 0.79 -0.35 0.05 
One or more 1° relatives with ovarian cancer -0.23 0.11 0.02 0.93 -0.03 0.87 
One or more 2° relatives with ovarian cancer -0.05 0.78 -0.14 0.47 0.004 0.98 
* Biomarker values have been log transformed and standardized to mean=0 and SD=1; therefore, each factor’s coefficient can be interpreted as the deviation from zero for a one 
unit change in the corresponding factor. 
 
 
 
Table 4.  Final multivariate linear regression models for CA125, mesothelin, and HE4. 
Overall Model Fit  
Marker Adjusted R2 F-statistic p-
value 
 
Variable  
 
Coefficient* 
 
p-value 
CA125   
 0.04 0.02 Talc use 0.39 0.02 
   Parous -0.28 0.05 
Mesothelin   
 0.06 0.008 Age at blood 
draw 
0.02 0.01 
   BMI -0.04 0.03 
HE4   
 0.22 0.001 Age at blood 
draw 
0.06 0.001 
   Age at 
menarche 
0.13 0.03 
* Biomarker values have been log transformed and standardized to mean=0 and SD=1; therefore, each 
factor’s coefficient can be interpreted as the deviation from zero for a one unit change in the 
corresponding factor. 
 
 
 
 
 
 
